

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 512 334 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
08.09.1999 Bulletin 1999/36

(51) Int Cl.⁶: **C12Q 1/68**
// C12Q1/70

(21) Application number: **92106989.4**

(22) Date of filing: **24.04.1992**

(54) Methods for detecting a target nucleic acid in a sample

Verfahren zum Nachweis von DNS in einer Probe

Procédé pour la détection d'ADN dans un échantillon

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI NL SE

(30) Priority: **02.05.1991 US 695201**

(43) Date of publication of application:
11.11.1992 Bulletin 1992/46

(60) Divisional application: **98110423.5 / 0 872 562**

(73) Proprietor: **F. HOFFMANN-LA ROCHE AG**
4002 Basel (CH)

(72) Inventor: **Higuchi, Russell G.**
San Francisco, California 94177 (US)

(74) Representative:
Roche Diagnostics Boehringer Mannheim
GMBH Dr. Knauer et al. Patent Department et al
Sandhofer Strasse 116
D-68305 Mannheim (DE)

(56) References cited:
EP-A- 0 200 362 EP-A- 0 487 218
WO-A-90/15881 BE-A- 1 000 572

- **NUCLEIC ACIDS RESEARCH** vol. 19, no. 1, 11 January 1991, LONDON pages 109 - 116
S.T.ISAACS ET AL. 'Post-PCR sterilization: development and application to an HIV-1 diagnostic assay'
- **JOURNAL OF MOLECULAR BIOLOGY** vol. 78, no. 4, 25 August 1973, NEW YORK US pages 703 - 714
J.P.RICHARDSON 'Mechanism of ethidium bromide inhibition of RNA polymerase'
- **DATABASE WPIL** Week 8651, Derwent Publications Ltd., London, GB; AN 86-338273 & SU-A-1 231 077 (APPL MICROBIOL RES) 15 May 1986
- **BIOTECHNOLOGY** vol. 10, no. 4, April 1992, NEW YORK US pages 413 - 417
R.HIGUCHI ET AL. 'Simultaneous amplification and detection of specific DNA sequences'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention provides improved methods for detecting a target nucleic acid in a sample and for monitoring the increase in a double-stranded DNA during amplification of a target nucleic acid in a sample as also a kit for amplifying a target nucleic acid.

[0002] The novel methods for simultaneous nucleic acid amplification and detection enhance the speed and accuracy of prior detection methods and eliminate the need for sample processing following amplification. In a preferred embodiment, the method provides a modification of the polymerase chain reaction and utilizes agents whose fluorescence is enhanced upon binding double-stranded DNA. The methods provided herein have numerous applications, particularly in the fields of molecular biology, medical diagnostics and forensic sciences.

[0003] The disclosed nucleic acid detection methods offer the advantages of speed and simplicity over prior methods for detecting amplified nucleic acids. Nucleic acid detection techniques in general are particularly useful in medical diagnostic assays. For example, U.S. Patent No. 4,358,535 discloses a method for detecting pathogens by spotting a sample (e.g., blood, cells, saliva, etc.) on a filter, lysing the cells and fixing the DNA through chemical denaturation and heating. Then, labeled DNA probes are added and allowed to hybridize with the fixed sample DNA. Hybridization indicates the presence of the pathogen's DNA.

[0004] Nucleic acid detection using oligonucleotide probes has become a standard method for specific target detection. Numerous modifications of the method have been described, including culturing the target cells or organisms in situ on the filter, increasing the amount of target nucleic acid available for detection. Generally, these methods require that the DNA sample is noncovalently bound onto a solid support such as nitrocellulose or nylon and then hybridized to a labeled target-specific probe.

[0005] The sensitivity and specificity of nucleic acid detection methods was greatly improved by the invention of the polymerase chain reaction (PCR). PCR is a process for amplifying nucleic acids and involves the use of two oligonucleotide primers, an agent for polymerization, a target nucleic acid template, and successive cycles of denaturation of nucleic acid and annealing and extension of the primers to produce a large number of copies of a particular nucleic acid segment. With this method, segments of single copy genomic DNA can be amplified more than 10 million fold with very high specificity and fidelity. PCR methods are disclosed in U.S. Patent No. 4,683,202.

[0006] Methods for detecting PCR products are particularly described in U.S. Patent No. 4,683,195. Those methods require an oligonucleotide probe capable of hybridizing with the amplified target nucleic acid. EP No. 237,362 also describes a PCR-based detection method termed "reverse dot blot", in which the probe, instead of the amplified DNA, is fixed to the membrane. According to the method, the target, rather than the probe, is labeled for hybridization. These methods require separate steps of amplification, capture, and detection and generally require several hours to complete. In the reverse dot-blot method, storage-stable target-specific reagents are preferred.

[0007] Alternative methods for detecting amplified nucleic acids describe simultaneous amplification and labeling of a target nucleic acid. The methods require that at least one amplification primer is labeled. The amplification primer can be labeled with, for example, a radioisotope for direct detection of the amplified product or labeled with a reagent suitable for capturing the product onto a solid support for subsequent detection.

[0008] Other means of detection include the use of fragment length polymorphism hybridization, allele-specific oligonucleotide (ASO) probes (Saiki et al., 1986, Nature 324:163), or direct sequencing via the dideoxy method using amplified DNA rather than cloned DNA. The fragment length polymorphism method detects insertions and deletions between PCR primers resulting in PCR products of different lengths, detectable by sizing. ASO methods are useful for detecting allelic sequence variations. In an example of ASO hybridization, the amplified DNA is fixed to a nylon filter by, for example, UV irradiation in a series of "dot blots," then allowed to hybridize with an oligonucleotide probe under stringent conditions. The probe may be labeled with, for example, horseradish peroxidase (HRP) and detected by the presence of a blue precipitate following treatment with suitable oxidation reagents.

[0009] Further is known an alternative assay method for detecting amplified nucleic acids. The process employs the 5' to 3' nuclease activity of a nucleic acid polymerase to cleave annealed, labeled oligonucleotides from hybridized duplexes and release labeled oligonucleotide fragments for detection. The method is suitable for detecting PCR products and requires a primer pair and a labeled oligonucleotide probe having a blocked 3'-OH terminus to prevent extension by the polymerase.

[0010] Due to the enormous amplification possible with the PCR process, small levels of DNA carryover from samples with high DNA levels, positive control templates, or from previous amplifications, can result in PCR product even in the absence of purposefully added template DNA. Higuchi and Kwok, 1989, Nature 339:237-238, and Kwok and Orrego, in Innis et al., 1990, PCR Protocols: A Guide to Methods and Applications, Academic Press, Inc., San Diego, CA, describe particular methods and precautions for practicing PCR with a minimum of cross contamination. Because the possibility of introducing contaminating DNA to a sample will be increased as the amount of handling steps required for sample preparation, processing, and analysis is increased, it would be preferable to minimize sample handling, particularly after the amplification reaction is complete.

[0011] A number of agents have been described for labeling nucleic acids, whether probe or target, for facilitating detection of target nucleic acid. Suitable labels may provide signals detectable by fluorescence, radioactivity, colorimetry, X-ray diffraction or absorption, magnetism or enzymatic activity and include, for example, fluorophores, chromophores, radioactive isotopes (particularly ^{32}P and ^{125}I) electron-dense reagents, enzymes, and ligands having specific binding partners.

[0012] Labeling is achieved by a number of means, such as chemical modification of a primer or probe to incorporate a label or the use of polymerizing agents to incorporate a modified nucleoside triphosphate into an extension product. Intercalating agents noncovalently bind the stacked bases of nucleic acids and as a result the fluorescence of the agent either increases or shifts to a different wavelength. For example, U.S. Patent No. 4,582,789 describes several intercalating moieties including psoralens.

[0013] Fluorescent dyes are suitable for detecting nucleic acids. For example, ethidium bromide is an intercalating agent that displays increased fluorescence when bound to double-stranded DNA rather than when in free solution (Sharp et al., 1973, *Biochemistry* 12:3055). Ethidium bromide can be used to detect both single- and double-stranded nucleic acids, although the affinity of ethidium bromide for singlestranded nucleic acid is relatively low. Ethidium bromide is routinely used to detect nucleic acids following gel electrophoresis. Following size fractionation on an appropriate gel matrix, for example, agarose or acrylamide, the gel is soaked in a dilute solution of ethidium bromide. The DNA is then visualized by examining the gel under UV light (Maniatis et al., 1982 eds., *Molecular Cloning: A Laboratory Manual*, New York, Cold Spring Harbor Laboratory).

[0014] Alternative fluorescence based methods for detecting DNA have been described. For example, Morrison et al., 1989, *Anal. Biochem.*, 183:231-244 describe a two probe method for detecting target DNA. One probe is labeled with fluorescein, the other probe, complementary to the first, is labeled with a quencher for fluorescein emission. The probes are allowed to anneal with denatured DNA containing the target sequence, and the amount of fluorescence is determined. Fluorescence increases to the extent that the fluorescein probe binds to unlabeled, complementary DNA rather than the complementary, quenching probe.

[0015] Mabuchi et al., 1990, *Nucl. Acids Res.* 18(24):7461-7462 describe a method for detecting DNA fragments based on the AT content of the nucleic acid segment. Two fluorochromes are used to stain size fractionated DNA in an agarose gel. The selective binding properties of different fluorochromes for AT rich regions are used to distinguish electrophoresed DNA fragments.

[0016] U.S. Patent No. 4,257,774 describes the direct binding of fluorescent intercalators to DNA, e.g., ethidium salts, daunomycin, mepacrine and acridine orange, as well as 4'-diamidino- α -phenylindole to quantitate the DNA. Fluorescence polarization is used for characterization of nonfluorescent DNA binding compounds which compete with the DNA binding dyes.

[0017] Oser and Valet, 1990, *Angew. Chem. Int. Engl.* 29(10):1167, describe a nucleic acid detection scheme that requires two oligonucleotide probes complementary to adjacent sites on a target. The probes are labeled differentially with either a salicylate or a DTPA ligand bearing a fluorescence emitter, Tb^{III} . Hybridization of both probes to the target provides steric proximity of the two labels resulting in a measurable increase in Tb^{III} fluorescence. The modified probes are prepared specifically for each target to be detected.

[0018] EP No. 070,685 describes the use of fluorescent labeled polynucleotide probes in polynucleotide hybridization assays. According to the method, probes are prepared by attaching particular absorber-emitter moieties to the 3' and 5' ends of nucleic acid fragments. The fragments are capable of hybridizing to adjacent positions on a target DNA, so that, if both fragments are hybridized, the proximity of the absorber and emitter moieties results in detectable emitter fluorescence.

[0019] According to these methods, the fluorescent dye is introduced to the target DNA after all in vitro nucleic acid polymerization reactions have been completed. The inhibitory effects of intercalating agents on nucleic acid polymerases have been described in numerous publications (for example, Kornberg, 1974, *DNA Synthesis*, W.H. Freeman and Co., San Francisco; Richardson, 1973, *J. Mol. Biol.* 78:703-714).

[0020] DNA binding dyes are useful as antibiotics because of the inhibitory effects on nucleic acid replication processes that result from the agent binding to the template. EP No. 169,787 describes the use of intercalating agents for blocking replication of influenza or herpes virus. Kornberg (supra) describes a number of DNA binding agents, both intercalators and non-intercalators, and describes how each compound inhibits nucleic acid replication. At page 227, Kornberg specifically describes that ethidium bromide inhibits DNA replication.

[0021] EP 487 218 A1 also discloses a method for detecting or quantifying target nucleic acid using the polymerase chain reaction (PCR) and a marker of which a detectable property is changed upon reaction with or exposure to the nucleic acid wherein the change in the detected property is measured. The marker may be added after the PCR and measured or it may be added before the PCR and measured before and after the PCR. In a third aspect the marker may be measured during the PCR. This reference is only a reference under Art. 54(3) EPC and, therefore, has no bearing upon the inventive step of the present application.

[0022] A method for simultaneous amplification and detection of target nucleic acids would provide advantages over

prior detection methods. Such a method would minimize the problems of sample contamination inherent in any process involving a series of manipulative steps for discerning a positive or negative test result. By eliminating sample handling and processing steps, a method for simultaneous amplification and detection of target nucleic acids would increase the speed and accuracy of current diagnostic methods. The present invention addresses and solves these needs.

[0023] The present invention provides a method for detecting a target nucleic acid in a sample. The method comprises the steps of: (a) providing an amplification reaction mixture that comprises a sample, a DNA binding agent, wherein said agent is characterized as providing a detectable signal when bound to double-stranded nucleic acid which signal is distinguishable from the signal provided by said agent when it is unbound, and reagents for amplification; (b) determining the amount of signal produced by the mixture of step (a); (c) treating said mixture under conditions for amplifying the target nucleic acid; (d) determining the amount of said signal produced by the mixture of step (c); and (e) determining if amplification has occurred.

[0024] The invention is particularly suitable for practice in PCR amplification methods wherein a net increase in double-stranded DNA results in a change in signal strength or type. In a preferred embodiment, the DNA binding agent is a fluorescent DNA binding dye, such as ethidium bromide, and the signal is fluorescence.

[0025] Figure 1 demonstrates the increased fluorescence of the PCR mixture due to amplification of a specific target DNA in the presence of ethidium bromide. The experiment is described in detail in Example II.

[0026] Figure 2 demonstrates the target specificity of the present detection method and illustrates some of the quantitative aspects of the invention. The details of the experiment are provided at Example IV.

[0027] Figure 3 demonstrates the use of the present invention for genetic screening. The experiment is described in detail at Example V.

[0028] Figures 4A and 4B relate to the quantitative homogeneous assay described in Example VII. Figure 4A demonstrates that the increase in fluorescence in the positive samples is greater than two standard deviations away from the average of the negative samples. Figure 4B graphically describes a background subtraction method for measuring fluorescence.

[0029] Figures 5A and 5B demonstrate the results of an on-line, automated homogeneous amplification and detection system, according to the present invention as demonstrated in Example VIII. Figure 5A shows a fluorescence print-out from a PCR containing no target DNA and serves as a negative control. Figure 5B is a fluorescence print out from a PCR containing the appropriate target and demonstrates the continuous monitoring of the PCR and concurrent increase in PCR product.

[0030] The present invention provides improved methods for detecting nucleic acids and is especially suited for use in conjunction with amplification processes. The improved methods require neither an oligonucleotide probe nor a labeled amplification primer. The methods enable monitoring the accumulation of product while the amplification reaction is in progress. The invention also allows target specific quantitation. These methods are suitable for use in automated formats.

[0031] The methods disclosed offer vast improvements over prior methods for detecting amplified nucleic acids. According to the invention, amplified nucleic acids are detected without opening the reaction vessel once the amplification reaction is initiated and without any additional handling or manipulative steps subsequent to the reaction. Prior to the present invention, nucleic acid detection methods required a third oligonucleotide reagent as a probe, or a series of manipulative and time consuming steps for target detection, for example, capturing the product on a solid support, which steps are performed after amplification. In some procedures both capture and probe hybridization steps are required. The present invention eliminates the need for using a hybridizing probe reagent or a capture procedure for detecting the amplified target. In a clinical setting the methods of the invention offer speed, simplicity, and decreased opportunity for cross-contamination between samples, particularly between amplified and non-amplified samples. In addition, the present methods offer means for automated detection, monitoring and quantitation of amplification products during the amplification process and after the amplification reaction is complete.

[0032] The present methods require a detectable agent capable of binding doublestranded DNA. The detectable binding agent may be a fluorescent dye or other chromophore, enzyme, or agent capable of producing a signal, directly or indirectly, when bound to double-stranded DNA. The agent may be also characterized as binding to single-stranded DNA or RNA. It is only necessary that the agent is capable of producing a detectable signal when bound to a double-stranded nucleic acid that is distinguishable from the signal produced when that same agent is in solution or bound to a single-stranded nucleic acid.

[0033] In one embodiment, the DNA binding agent is an intercalating agent. As used herein, an intercalating agent is an agent or moiety capable of non-covalent insertion between stacked base pairs in the nucleic acid double helix. Intercalating agents, such as ethidium bromide, fluoresce more intensely when intercalated into double-stranded DNA than when bound to single-stranded DNA, RNA, or in solution. Other intercalating agents exhibit a change in the fluorescence spectra when bound to doublestranded DNA. For example, actinomycin D fluoresces red when bound to singlestranded nucleic acids, and green when bound to a double-stranded template. Whether the detectable signal increases, decreases or is shifted, as is the case with actinomycin D, any intercalating agent that provides a detectable

signal that is distinguishable when the agent is bound to double-stranded DNA or unbound is suitable for practicing the disclosed invention. For example, the interaction between DNA and another photoreactive psoralen, 4-aminomethyl-4'-5'-8-trimethylpsoralen (AMT) has been described (Johnson et al., 1981, Photochem. & Photobiol., 33:785-791. According to the reference, both the absorption at long wavelengths and fluorescence, decline upon intercalation of AMT into the DNA helix.

[0034] Non-intercalating DNA binding agents are also suitable. For example, Hoechst 33258 (Searle & Embrey, 1990, Nuc. Acids Res. 18(13):3753-3762) exhibits altered fluorescence with increasing amount of target. Hoechst 33258 is a member of a class of DNA-binding compounds commonly referred to as "groove binders." This group includes drugs like distamycin, netropsin and others. These compounds recognize and bind the minor groove of duplex DNA.

[0035] According to the present invention, a DNA binding agent produces a detectable signal directly or indirectly. The signal is detectable directly, such as by fluorescence or absorbance, or indirectly via a substituted label moiety or binding ligand attached to the DNA binding agent. For indirect detection any moiety or ligand that is detectably affected by proximity to double-stranded DNA is suitable.

[0036] According to the invention, the detectable binding agent is present in the amplification reaction during the amplification process. As amplification proceeds, the agent produces a detectable signal. Neither the agent nor the signal prevents amplification from proceeding. Consequently, the agent may be added to the reaction mixture prior to amplification or while the reaction is in progress. For example, the agent is included in an amplification buffer comprising appropriate reagents, such as salts and buffering agents. In this manner, it is not necessary to separately add the binding agent to the amplification reaction. For practice of the present invention, any DNA binding agent is suitable, so long as in the presence of that agent a net increase in the amount of double-stranded DNA present is reflected in a change signal intensity that is detectable directly or indirectly. In a preferred embodiment, the detectable signal is fluorescence.

[0037] The term "homogeneous detection assay" is used in the present specification to describe the claimed invention. For ease of understanding, the following definition is provided. Homogeneous detection assay refers to a method for coupled amplification and detection, wherein the process of amplification generates a detectable signal and the need for subsequent sample handling and manipulation to detect the amplified product is minimized or eliminated.

[0038] The present homogeneous assay is suitable for use in conjunction with oligonucleotide probes. For example, in one embodiment the use of an oligonucleotide probe, specific for detecting a particular target sequence, is included in the amplification reaction in addition to the DNA binding agent of the present invention. The probe, labeled with a quencher and fluorophore, hybridizes to the amplified target nucleic acid. In the presence of an agent for polymerization capable of 5' to 3' nucleolytic activity, the fluorophore and quencher, when bound to the target, are separated by degradation of the probe by the polymerase. The fluorescence of the unbound probe is detectably distinct from the fluorescence of the bound, and subsequently hydrolyzed probe. Thus, the fluorescence of the DNA binding agent enables detection that amplification has occurred, and the fluorescence of the hybridized probe indicates target specific amplification. So long as amplification is detectable without opening the reaction vessel, or further processing steps once amplification is initiated, the method is within the present definition of a homogeneous assay.

[0039] The term "amplification reaction system" refers to any in vitro means for multiplying the copies of a target sequence of nucleic acid. Such methods include but are not limited to PCR, DNA ligase chain reaction (LCR), Q RNA replicase and RNA transcription-based amplification systems (TAS and 3SR).

[0040] The term "amplifying" which typically refers to an exponential increase in target nucleic acid is being used herein to describe both linear and exponential increases in the numbers of a select target sequence of nucleic acid.

[0041] The term "amplification reaction mixture" refers to an aqueous solution comprising the various reagents used to amplify a target nucleic acid. These include enzymes, aqueous buffers, salts, amplification primers, target nucleic acid, and nucleoside triphosphates. Depending upon the context, the mixture can be either a complete or incomplete amplification reaction mixture.

[0042] The systems described below are practiced routinely by those of skill in the relevant art. They have been described in detail by others and are summarized below. This invention is not limited to any particular amplification system. As other systems are developed, those systems may benefit by practice of this invention. A recent survey of amplification systems was published in Bio/Technology 8:290-293, April 1990. The following four systems are described below to provide an understanding of the breadth of the present invention.

[0043] Amplification of DNA by PCR is disclosed in U.S. Patent Nos. 4,683,195 and 4,683,202. Methods for amplifying and detecting nucleic acids by PCR using a thermostable enzyme are disclosed in US. Patent No. 4,965,188.

[0044] PCR amplification of DNA involves repeated cycles of heat-denaturing the DNA, annealing two oligonucleotide primers to sequences that flank the DNA segment to be amplified, and extending the annealed primers with DNA polymerase. The primers hybridize to opposite strands of the target sequence and are oriented so that DNA synthesis by the polymerase proceeds across the region between the primers, effectively doubling the amount of the DNA segment. Moreover, because the extension products are also complementary to and capable of binding primers, each

successive cycle essentially doubles the amount of DNA synthesized in the previous cycle. This results in the exponential accumulation of the specific target fragment, at a rate of approximately 2^n per cycle, where n is the number of cycles.

[0045] In the disclosed embodiment, Taq DNA polymerase is preferred although this is not an essential aspect of the invention. Taq polymerase, a thermostable polymerase, is active at high temperatures. Methods for the preparation of Taq are disclosed in U.S. Patent No. 4,889,818. However, other thermostable DNA polymerases isolated from other *Thermus* species or non *Thermus* species (e.g., *Thermus thermophilus* or *Thermotoga maritima*), as well as non-thermostable DNA polymerase such as T4 DNA polymerase, T7 DNA polymerase, *E. coli* DNA polymerase I, or the Klenow fragment of *E. coli*, can also be used in PCR.

[0046] As used herein, the term "primer" refers to an oligonucleotide capable of acting as a point of initiation of DNA synthesis when annealed to a nucleic acid template under conditions in which synthesis of a primer extension product is initiated, i.e., in the presence of four different nucleotide triphosphates and a DNA polymerase in an appropriate buffer ("buffer" includes pH, ionic strength, cofactors, etc.) and at a suitable temperature.

[0047] The nucleoside-5'-triphosphates utilized in the extension process, typically dATP, dCTP, dGTP, and dTTP, are present in total concentration typically ranging from 400 μ M to 4.0 mM during the extension reaction, although preferably the concentration is between 500 μ M and 1.5 mM.

[0048] The choice of primers for use in PCR determines the specificity of the amplification reaction. Primers used in the present invention are oligonucleotides, usually deoxyribonucleotides several nucleotides in length, that can be extended in a template-specific manner by the polymerase chain reaction. The primer is sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization and typically contains 10-30 nucleotides, although that exact number is not critical to the successful application of the method. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.

[0049] Synthetic oligonucleotides can be prepared using the triester method of Matteucci et al., 1981, *J. Am. Chem. Soc.* 103:3185-3191. Alternatively automated synthesis may be preferred, for example, on a Biosearch 8700 DNA Synthesizer using cyanoethyl phosphoramidite chemistry.

[0050] For primer extension to occur, this primer must anneal to the nucleic acid template. Not every nucleotide of the primer must anneal to the template for extension to occur. The primer sequence need not reflect the exact sequence of template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer with the remainder of the primer sequence being complementary to the template. Alternatively, non-complementary bases can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the template for annealing to occur and allow synthesis of a complementary DNA strand.

[0051] Amplification systems such as PCR require a target nucleic acid in a buffer compatible with the enzymes used to amplify the target. The target nucleic acid can be isolated from a variety of biological materials including tissues, body fluids, feces, sputum, saliva, plant cells, bacterial cultures, and the like.

[0052] In general, the nucleic acid in the sample will be a sequence of DNA, most usually genomic DNA. However, the present invention can also be practiced with other nucleic acids, such as messenger RNA, ribosomal RNA, viral RNA, or cloned DNA. Suitable nucleic acid samples include single or double-stranded DNA or RNA for use in the present invention. Those of skill in the art will recognize that whatever the nature of the nucleic acid, the nucleic acid can be amplified merely by making appropriate and well recognized modifications to the method being used.

[0053] To amplify a target nucleic acid sequence in a sample, the sequence must be accessible to the components of the amplification system. In general, this accessibility is ensured by isolating the nucleic acids from a crude biological sample. A variety of techniques for extracting nucleic acids from biological samples are known in the art, for example, those described in Maniatis et al., *Molecular Cloning: A Laboratory Manual*, New York, Cold Spring Harbor Laboratory, 1982; Arrand, *Preparation of Nucleic Acid Probes*, in pp. 18-30, *Nucleic Acid Hybridization: A Practical Approach*, Ed Hames and Higgins, IRL Press, 1985; or in *PCR Protocols*, Chapters 18-20, Innis et al., ed., Academic Press, 1990.

[0054] The PCR process is most usually carried out as an automated process with a thermostable enzyme. In this process, the reaction mixture is cycled through a denaturing temperature range, a primer annealing temperature range, and an extension temperature range. A machine specifically adapted for use with a thermostable enzyme is disclosed more completely in EP No. 236,069 and is commercially available.

[0055] LCR is described in PCT Patent Publication No. WO 89/09835. The process involves the use of ligase to join oligonucleotide segments that anneal to the target nucleic acid. LCR results in amplification of an original target molecule and can provide millions of copies of product DNA. Consequently, the LCR results in a net increase in double-stranded DNA. The present detection methods are applicable to LCR, as well as PCR. LCR requires an oligonucleotide probe for detecting the product DNA. When used in conjunction with the disclosed methods for detecting amplification products, a probe step is unnecessary, and the LCR result is immediately detectable.

[0056] Another amplification scheme exploits the use of the replicase from the RNA bacteriophage Q β . In this amplification scheme, a modified recombinant bacteriophage genome with a sequence specific for the targeted sequence is initially hybridized with the nucleic acid to be tested. Following enrichment of the duplexes formed between the

bacteriophage probe and the nucleic acid in a sample, Q β replicase is added, which, upon recognizing the retained recombinant genome, begins making large numbers of copies.

[0057] The Q β system does not require primer sequences and there is no heat denaturation step as with the PCR and LCR amplification systems. The reaction occurs at one temperature, typically 37°C. The preferred template is a substrate for the Q β replicase, midvariant-1 RNA. A very large increase in the templates is achieved through the use of this system. A review of this amplification system can be found in the International Patent Application Pub. No. WO 87/06270 and in Lizardi et al., 1988, *Bio/Technology* 6:1197-1202.

[0058] The 3SR system is a variation of an in vitro transcription based amplification system. A transcription-based amplification system (TAS) involves the use of primers that encode a promoter to generate DNA copies of a target strand and the production of RNA copies from the DNA copies with an RNA polymerase. See, e.g., Example 9B of U. S. Patent No. 4,683,202 and EP No. 310,229. The 3SR System is a system which uses three enzymes to carry out an isothermal replication of target nucleic acids.

[0059] The system begins with a target of single-stranded RNA to which a T7 RNA DNA primer is bound. By extension of the primer with reverse transcriptase, a cDNA is formed, and RNaseH treatment frees the cDNA from the heteroduplex. A second primer is bound to the cDNA and a double stranded cDNA is formed by DNA polymerase (i.e., reverse transcriptase) treatment. One or both of the primers encodes a promoter, i.e., the promoter for T7 RNA polymerase, so that the double-stranded cDNA is transcription template for T7 RNA polymerase.

[0060] Transcription competent cDNAs yield antisense RNA copies of the original target. The transcripts are then converted by the reverse transcriptase to double standard cDNA containing double-stranded promoters, optionally on both ends in an inverted repeat orientation. These DNAs can yield RNAs, which can reenter the cycle. A more complete description of the 3SR system can be found in Guatelli et al., 1990, *Proc. Natl. Acad. Sci. USA* 87:1874-1878, and EP No. 329,822. The TAS system is also described in Gingeras et al., in Innis et al. eds., 1990, *PCR Protocols*, Academic Press, San Diego.

[0061] The embodiments of the invention exemplified herein disclose the process for detecting amplified nucleic acids in conjunction with PCR. Accordingly, when used in a PCR-based method, the DNA binding agent is characterized as an agent that will not prevent primer annealing, primer extension along a complementary template, or strand separation of a DNA duplex.

[0062] In the process described herein, a sample is provided which contains, or is suspected of containing, a particular oligonucleotide sequence of interest, the "target nucleic acid." The target may be RNA or DNA or an RNA/DNA hybrid. The target may be single stranded or double stranded. Target preparation will be carried out in a manner appropriate for the particular amplification process to be implemented. For example, in a PCR method where the target nucleic acid is single-stranded DNA, such as mRNA, the target may be first reverse-transcribed into cDNA, prior to amplification.

[0063] Methods for reverse transcribing RNA into cDNA are well known and described in Maniatis et al., *supra*. Alternatively, preferred methods for reverse transcription utilize thermoactive DNA polymerases. The present specification teaches that intercalating agents do not prevent DNA polymerase activity. Consequently, the present method provides a homogeneous detection assay for RNA targets as well as DNA targets.

[0064] In another embodiment of the present invention, nested primers are used (Mullis et al., 1986, *Cold Spring Harbor Symposium on Quantitative Biology* 51:263). This method may be preferred when the amount of nucleic acid in a sample is extremely limited, for example, where archival, paraffin embedded samples are used. When nested primers are used, the nucleic acid is first amplified with an outer set of primers. This amplification reaction is followed by a second round of amplification cycles using an inner set of primers. Examples VI and VII describe modifications of nested primer methods that provide superior results without necessitating the additional sample handling required by using nested primers in successive rounds of amplification cycles.

[0065] According to the present invention, the generation of amplification products can be monitored while the reaction is in progress. An apparatus for detecting the signal generated by the binding agent, can be used to detect, measure, and quantify the signal before, during, and after amplification. Of course, the particular type of signal may dictate the choice of detection method. For example, in a preferred embodiment of the invention, fluorescent DNA binding dyes are used to label PCR products. The dyes intercalate, or bind, the double-stranded PCR products, and consequently, the resulting fluorescence increases as the amount of double-stranded DNA increases. The amount of fluorescence can be quantitated by measurement using a spectra-fluorometer with or without opening the PCR vessel. Examples VII and VIII demonstrate this aspect of the invention.

[0066] In Example VIII the fluorescence of the positive control sample was well above background measurements. Because signal generation was measured without having to open the reaction tube, this method of detection is readily adaptable to an automated format in which signal is monitored throughout the amplification process. Example VIII demonstrates an automated, on-line PCR detection method: a fiber optic lead was used to input excitation light directly to a PCR tube in a heating/cooling block. The same fiber optic was used to return fluorescent emissions back to the spectrafluorometer, where the value was read.

[0067] In preferred methods for PCR, the amplification reaction is carried out as an automated process. A thermo-

cycler currently available uses a heat block capable of holding up to 48 reaction tubes. Consequently, 48 amplification reactions can be carried out simultaneously. The present invention permits PCR product detection in all 48 samples, without handling the samples, opening tubes, or interrupting the cycling reaction. A suitable optical system moves the excitation light from the source to the reaction tube and measures the emission light from each tube. For example, multiple fiber optic leads simultaneously read all PCR tubes undergoing thermocycling. However, only a single fluorometer is needed to read fluorescence from the reaction tubes, as each fiber optic can be read rapidly one at a time, for example, during the time frame of a PCR temperature soak. Alternatively, it will be obvious to one skilled in the art that such a detection system is not necessarily limited to a particular thermocycler machine or number of reaction vessels. However, the description of the 48 well thermocycler serves to demonstrate this aspect of the present invention.

[0068] So long as the reaction wells, or tubes, are light sealed to prevent external light sources from influencing fluorescence detection, any over plate, tube cap, or lid apparatus that comprises or can be attached to, a fiber optic lead is suitable. In the embodiment of the invention at Example VIII, the reaction tube lids were removed to accommodate the fiber optic. However, use of a reaction vessel that has a clear or translucent cap eliminates the need to insert the cable into the tube. It will be apparent that reaction tubes able to accommodate a fiber optic cable, without the cable physically contacting the amplification reaction components, is desirable. In a spectrofluorometer capable of heating and cooling a surface, or vessel, an optic fiber is not required. The optic fiber is only necessary where a thermocycler and spectrofluorometer are housed independently.

[0069] An analogous detection scheme is suitable in a 96-well microtiter format. This type of format is frequently desirable in clinical laboratories for large scale sample screening, for example, for genetic analysis such as screening for sickle-cell anemia or the AIDS virus in blood bank screening procedures. The present invention is suitable for this type of analysis and eliminates the need for the numerous washing and extraction procedures that are required with known "in-well" assay procedures such as ELISA type formats or other optical density-based methods (Kolber et al., 1988, J. of Immun. Meth. 108:255-264; Huschtscha et al., 1989, In Vitro Cell and Dev. Biol. 25(1):105-108; Voller et al., 1979, The Enzyme Linked Immunosorbent Assay, Dynatech Labs, Alexandria, VA.).

[0070] The present detection methods also allow direct fluorescence measurement using an apparatus similar to ELISA plate reader, but designed to excite and measure fluorescence. For example, the CytoFluor™ 2300 machine manufactured by Millipore is suitable in such a method. It is appropriate to "read" the microtiter plate before and after thermocycling for determining background fluorescence. Alternatively, an apparatus providing a continuous determination of fluorescence is useful for monitoring the increase in PCR product during the amplification reaction.

[0071] In another embodiment of the invention, following amplification, the size of the amplified product is determined without the use of a probe or size fractionation methods such as HPLC or gel electrophoresis. The invention is particularly useful for determining if amplification has occurred and simultaneously distinguishing the amplified target product from, for example, primer-dimer and high molecular weight DNA.

[0072] In a preferred embodiment of the invention, the detectable binding agent is an intercalating fluorescent dye. The present examples describe that ethidium bromide is included in the amplification reaction mixture. Ethidium bromide, like other DNA binding dyes, such as acridines, proflavine, acridine orange, acriflavine, fluorcoumanin, ellipticine, daunomycin, chloroquine, distamycin D, chromomycin, homidium, mithramycin, ruthenium polypyridyls, and anthramycin, exhibit altered fluorescence emissions when bound to double-stranded DNA. In an amplification reaction, a large amount of double-stranded DNA is generated from a starting template. Consequently, when this occurs in the presence of an intercalating fluorescent dye, a net increase in DNA-dependent fluorescence results. The target specificity of PCR and the use of appropriate positive and negative controls ensure that a detectable increase in fluorescence is due to the presence of the amplified target nucleic acid.

[0073] The present specification includes several examples demonstrating various aspects of the homogeneous detection assay. The particular embodiments describe that ethidium bromide is present in the PCR at a concentration of 0.53 to 1.27 μM although a concentration of 0.08 μM (0.03 $\mu\text{g/ml}$) to 40.6 μM (16 $\mu\text{g/ml}$) is also suitable; however, an ethidium bromide concentration in the PCR mix in the range of 0.15 μM (0.06 $\mu\text{g/ml}$) to 20.3 μM (8 $\mu\text{g/ml}$) is preferred. It will be readily apparent to those of ordinary skill in the art how to determine a suitable concentration of alternative DNA binding agents by empirical adjustment. A suitable concentration of agent is any amount that provides a signal that is distinguishable when a net increase in doublestranded DNA has occurred in an amplification reaction. Consequently, the preferred concentration of agent included in the amplification reaction mix may vary depending on the amount of double-stranded non-target DNA (i.e., background genomic DNA), the copy number and amount of target, the quantity and fluorescence of the amplification primers and the particular agent utilized. For example, a standard curve using a known amount of target and varying the amount of binding agents may be appropriate. The fluorescent dye is added to the PCR mixture before starting temperature cycling. A suitable fluorescent dye does not prevent amplification from occurring. It will be obvious to one of ordinary skill in the art to determine the suitability of any novel dye in the method. Example I demonstrates that PCR amplification occurs in the presence of detectable amounts of ethidium bromide.

[0074] The emission spectrum of ethidium bromide peaks at 650 nm for unbound ethidium bromide and at 611 nm

when the agent is bound to double-stranded DNA. However, because the emission spectra of bound and unbound ethidium bromide have distinct peaks, with bound ethidium emitting at a lower wavelength, discrimination between bound and unbound ethidium is enhanced by detecting emission at a non-peak wavelength that is less than the peak for bound ethidium. In the disclosed embodiment at Example VII, the fluorescence emission of the sample was detected at 570 nm. At Example VIII, the excitation wavelength was set at 500 nm and emission detection was set at 570 nm.

[0075] It is not essential that the detection or excitation wavelength is optimized for practice of the invention. For example, in Example II, a U.V. light box with an excitation wavelength at 300 nm and detection by photography through a red filter is suitable. A spectra fluorometer, depending on the features of the particular machine utilized, offers the opportunity to set the excitation and emission wavelength, as well as bandwidth. It will be obvious to one of ordinary skill in the art how to determine the wavelength and bandwidth settings for a particular DNA binding agent to be detected. Thus, although each agent has a discrete fluorescence spectrum, a broad range of detection wavelengths are suitable for practicing the invention, as exemplified herein. General guidance is found in, for example, The Merck Index, eds. Budavari et al., 1989, Merck Co. Inc. Rahway, NJ, where peak emission wavelengths for particular fluorescent agents bound and unbound to helical DNA are described at each entry. Similarly, the Molecular Probes Inc., Eugene, Oregon, Catalogue, 1990, by Haugland is a suitable reference for describing DNA binding agents useful in the present invention.

[0076] In general, it is preferred but not essential that the DNA polymerase is added to the PCR reaction mixture after both the primer and template are added. Alternatively, for example, the enzyme and primer are added last or the PCR buffer or template plus buffer are added last. It is generally desirable that at least one component that is essential for polymerization not be present until such time as the primer and template are both present, and the enzyme can bind to and extend the desired primer/template substrate.

[0077] Methods for reducing the effects of cross contamination of amplification reactions require the introduction of unconventional bases into the amplified product and exposing carryover to enzymatic and/or physical chemical treatment which effectively render the product incapable of serving as a template for subsequent amplifications. The homogeneous detection assay described herein is suitable in conjunction with sterilization methods. These methods enhance the accuracy and reliability of amplification results by eliminating steps, and thereby minimizing product handling, which reduces carryover. The sterilization method provides additional assurance that carryover template is eliminated.

[0078] Preferably, the DNA binding agent is storage stable and can be included as a component in a PCR reagent buffer. Thus, the invention provides novel reagents suitable for commercialization in a kit format. Such a reagent may contain a solution of the DNA binding agent in a kit for detecting nucleic acids by PCR. Alternatively, the reagent might contain a DNA binding agent, as well as other PCR buffer components such as Tris-HCl, KCl, and $MgCl_2$, each in appropriate concentrations for carrying out PCR. In one embodiment, a kit includes a buffer comprising ethidium bromide at a suitable concentration to provide, in an amplification reaction, a final ethidium bromide concentration in the range of 0.15 μM to 20.3 μM . The buffer may additionally contain any or all of the following reagents: Tris-HCl, pH 8.0-8.3; KCl, and $MgCl_2$ each in appropriate concentrations for PCR amplification. Kits for detecting amplified nucleic acids are also envisioned as including any of the following: an agent for polymerization, dNTPs, appropriate primers, and a positive control template.

[0079] U.S. Patent No. 4,683,202 describes methods for preparing and using primers for PCR which have non-complementary sequences added to the 5' end. These "tails" are useful for engineering particular restriction sites or other purposes, because during PCR, the non-complementary tail sequence is incorporated into the double-stranded PCR product. Particular tail sequences provide binding targets for specific dyes. For example, Hoechst 33258 (Searle and Embrey, 1990, Nuc. Acids Res. 18:3753-3762) preferentially binds A-T base pairs. A PCR primer synthesized with a long A-T rich 5' tail provides a relatively A-T rich PCR product in comparison with genomic DNA. Using Hoechst 33358 the A-T rich PCR product has increased fluorescence relative to genomic DNA and, consequently, is useful for increasing signal strength in the presence of genomic DNA.

[0080] Similarly, DAPI forms a fluorescent complex with AT rich DNA (Kapuscinski & Szer, 1979, Nuc. Acids Res., 6(112):3519). In contrast, Actinomycin D forms a fluorescent complex with G-C rich DNA (Jain and Sobell, 1972, J. Mol. Biol. 68:21). Thus, the present invention is suitable for monitoring the amount of two distinct target nucleic acids in one reaction vessel, by including two fluorochromes in the reaction mixture during amplification. It is only necessary that one fluorochrome has sequence specificity and that sequence is included in the tail (i.e., 5' end) of a primer to one of the two target nucleic acids. The emission spectra for each fluorochrome is separately determined during and/or after amplification by a spectra fluorometer. Thus, the invention is particularly useful for quantitative comparisons of two different nucleic acid targets in the same sample and as such may be useful for determining the extent of, for example, an infection or disease if one target is a sequence present in all cells and the other is present in a pathogen.

[0081] Similar agents with distinct binding properties permit multiplex PCR methods for detecting several targets in one sample without ever opening the reaction vessel once the amplification reaction is initiated. Fluorescent DNA binding dyes may each have different emissions and excitation spectra. In a clinical setting, different DNA binding dyes having different DNA sequence specificities are useful for indicating the presence of distinct targets.

[0082] The present invention is suitable in conjunction with methods using an internal standard to determine either the relative amount of a target or accurately quantitate the amount of target present prior to amplification.

[0083] In another embodiment, the present invention provides means for determining the intactness of a DNA sample. For example, forensic analysis often involve samples containing partially degraded target, such as an archival sample.

The ability to monitor the generation of PCR product, demonstrated in Example VIII, allows comparison of the amplification profile of a DNA sample with respect to a small PCR product and a large PCR product, in separate reactions. If there is no degradation, monitoring the increase in double-stranded DNA shows that both reactions reach plateau at approximately the same cycle. If there is degradation, the small product would reach plateau sooner than the large fragment due to the presence of more intact target molecules.

[0084] It will be apparent to those of ordinary skill in the art that the homogeneous detection assay provided herein is suitable for a wide variety of applications, including, for example, genetic screening, forensic human identification, pathogen detection, and quantitation, environmental monitoring or tagging and tracing materials with nucleic acid.

[0085] In one embodiment, the detectable signal is fluorescence. Fluorescence is suitable for use in qualitative as well as quantitative methods. Qualitative detection can be made simply and rapidly by visual inspection of the reaction tubes by exposure to UV light. This type of rapid, highly sensitive assay is desirable as a rapid screen for the presence of a pathogen or of a particular gene sequence causative of or associated with a disease state. The present invention provides means for cutting costs by a plus/minus pre-screen for the presence of any member of a group of targets. Amplifications for many different such targets would allow this if it may be expected that most samples are negative, e.g., environmental monitoring for pathogen detection systems. Multiplex PCR is a process for including a number of distinct primer pairs in one amplification reaction (Gibbs et al., 1989, in PCR Technology ed. Erlich, Stockton Press, NY). A homogeneous detection assay using multiple primer pairs to assay a wide range of potential targets is then followed by more complex typing procedures only on positive samples. This pre-screen saves the cost of performing the more complex typing procedure on negative samples and/or performing repeated tests on negative samples.

[0086] The present methods for homogeneous detection of target nucleic acids are also suitable for quantitation of a particular target. Whether the methods are automated or manually performed, quantitation can be accomplished by a number of means. For example, a serial dilution of the sample, in parallel with a serial dilution of a known standard, provides a series of templates, which, following PCR and signal detection, are suitable for quantitating the amount of starting material in the known sample. Similarly, because fluorescence can be determined between cycles during the course of a PCR, the exponential phase of PCR and the cycle at which the level of product reaches the plateau phase, can be readily determined. The more target DNA present at the start of PCR, the sooner the reaction reaches plateau, i.e., the point when the rate of product accumulation begins to diminish. Because the number of cycles needed to reach plateau is directly related to the amount of target present in the sample, monitoring fluorescence while PCR is in progress serves to quantitate small amounts of DNA.

[0087] The invention is suitable for detecting amplified nucleic acids in the presence of double-stranded genomic DNA. Background levels of DNA as high as 0.5 g or more will not obscure a positive assay result. The target nucleic acid can be a cloned segment, a repeat sequence, such as a multi-copy gene or tandem repeat, a single copy gene, or an infectious agent present in a concentration as low as one copy per 70,000 cells. The starting template is RNA or DNA because PCR provides a net increase in double-stranded nucleic acid starting from either template nucleic acid.

[0088] The target nucleic acid may be a rare sequence, such as a single copy of AIDS virus DNA in a background of human genomic DNA from more than 70,000 cells. In such an instance, procedures for increasing specificity serve to insure that amplification provides a net gain in double-stranded DNA only in response to the presence of the target sequence, and that net gain is detectable in the presence of high background of genomic DNA. U.S. Patent No. 4,683,195 demonstrates the use of nested primers to decrease the background in the amplification of single copy genes.

[0089] The procedure for nested amplification in U.S. Patent No. 4,683,195 requires a first primer pair to amplify a target sequence and a second primer pair to amplify a subsegment of the PCR product formed from the first amplification reaction. Following the first PCR, the reaction mixture is diluted 10-fold to reduce the concentration of the first primer pair, and the second primer pair is introduced into the reaction mixture. However, because a particular advantage of the present invention lies in the elimination of steps, the additional steps of stopping an amplification reaction to dilute the sample and adding a second primer pair are not desirable.

[0090] To address this issue, modified nested amplification procedures are provided. The present nested primer methods are vastly improved over prior nested primer procedures for amplifying nucleic acids. These methods provide enhanced specificity and are applicable in any PCR-based amplification scheme. However, in the present disclosure, these procedures are described used in a homogeneous assay.

[0091] In one modified nested primer method, a third primer, internal to a flanking pair of PCR primers is included in a PCR reaction for amplifying a particular target segment. The third primer has an annealing/melting temperature, when it is hybridized to its complementary target strand, that is lower than that of the flanking primer. This property can be imparted to the primer by a shorter length and/or lower G-C content. For the first 15-20 PCR cycles, the temperature during the extension phase of each PCR cycle is maintained sufficiently high, i.e. approximately 65°C to prevent the

short primer from annealing specifically and initiating amplification. The flanking primers anneal sufficiently such that PCR proceeds normally at the high extension temperature. However, the primer flanking the third primer is present at a low concentration. In the method, prior to amplification plateau, when the supply of limiting primer is almost exhausted, the annealing temperature is decreased to approximately 42°C. At this temperature, the third primer "drops in" and proceeds to amplify the target for the remaining 15 or so cycles.

[0092] In an alternative method for nested primer amplification, the need for a low concentration of one primer is eliminated. The flanking primer is synthesized with a G-C rich tail. Because the non-complementary primer tail sequence is incorporated into the PCR product after two cycles of amplification, the G-C tails serves to raise the temperature necessary for denaturing the PCR product because of the increased thermostability of G-C pairs versus A-T pairs (Myers et al., 1989, in PCR Technology ed. Erlich, Stockton Press, New York). The resulting difference in the denaturing temperature between the nested and flanking PCR product is then exploited to effectively shut down amplification from the tailed flanking primer. Once PCR product is made from the flanking primers, the denaturation temperature is lowered, i.e., from 96°C to 86°C, so that the temperature is too low for amplification of the flanking PCR product, but is high enough to allow amplification of the nested PCR product. The annealing temperature may also be manipulated, as in the "drop-in" method, to initiate synthesis from the nested primer when desired.

[0093] It would be obvious to one of ordinary skill in the art to empirically determine the appropriate denaturation and annealing temperatures and program a thermocycler accordingly. This "drop-out primer" method provides means for including high concentrations of the flanking primer to maintain PCR efficiency, and allow the amplification initiated by that primer to be terminated during the reaction as desired. This particular method for nested primer amplification is demonstrated in Examples VI and VII.

[0094] The following examples serve to illustrate various aspects of the present invention. The primer sequences used are listed at the end of example VIII.

Example I

[0095] This example demonstrates the ability of PCR to proceed in the presence of ethidium bromide.

[0096] Two PCRs were carried out as follows. Each 100 µl PCR contained: 50 ng human DNA, 10 mM Tris-HCl pH 8, 50 mM KCl, 4 mM MgCl₂, 250 µM each dNTP, 2.5 units Taq polymerase (Perkin-Elmer Cetus Instruments, Norwalk Connecticut), 20 picomole each primer GH26 (SEQ ID NO: 1) and GH27 (SEQ ID NO: 2). The human DNA was purified from a human B-cell line. DNA was prepared according to the method described by Maniatis (supra.). An oil overlay was added to each reaction to prevent evaporation.

[0097] The two PCRs were conducted under identical conditions except that 0.51 µM of ethidium bromide (Sigma) was included in one reaction. A thermocycler purchased from Perkin-Elmer Cetus Instruments was programmed with the following cycling parameters; denature at 96°C, hold for 1 minute, anneal at 55°C, hold for 1 minute, extend at 72°C, hold for 1 minute. This profile was repeated for 32 cycles. After amplification 5 µl of each PCR was analyzed by gel electrophoresis using a 3% NuSieve agarose gel (FMC). The gel was stained with ethidium bromide by standard methods and the amount of PCR product made in the two reactions was compared. The results demonstrated that the amount of amplified DNA produced in the presence of ethidium bromide was indistinguishable from the amount of PCR product made in the absence of the dye. Additionally, the specificity of the PCR, measured by the ability to produce DNA fragments of the expected size, was unchanged.

Example II

[0098] This example shows that the specificity of PCR is sufficient for fluorescence-based, homogeneous detection of target nucleic acids. The experiment described in Example I was expanded upon to determine whether target specific ethidium bromide fluorescence is readily visible using standard PCR conditions. Therefore, five 100 µl reaction mixtures were prepared containing 10 mM Tris-HCl pH8, 50 mM KCl, 2.5 mM MgCl₂, 1.27 µM ethidium bromide, 150 µM each dNTP, 2.5 units Taq polymerase. Primers and target DNA were included as described below. Primer pair GH15 (SEQ ID NO: 3) and GH16 (SEQ ID NO: 4) are specific for amplifying DQα; and do not amplify DRβ1 target DNA. DQα target DNA was prepared by amplifying the human DQα; gene as described in Example I. Following amplification, the DQα PCR product was diluted to provide ~2 x 10⁷ copies (5 pg) of amplified DNA per amplification. The DQα product was used as a positive control. DRβ1 target DNA was prepared using primer pair GH46 (SEQ ID NO: 5) and GH50 (SEQ ID NO: 6) to amplify the DRβ1 gene in a PCR using human genomic DNA. The PCR product was diluted to provide ~2 x 10⁷ copies of DRβ1 DNA and used in Reaction 4, below, as a negative control. The five reaction mixtures contained primers and target as follows:

Reaction 1 - No primers + DQα Target

Reaction 2 - Primers + DQα target

Reaction 3 - Primers + DQ α target

Reaction 4 - Primers + DR β 1 target

Reaction 5 - Primers + no target

5 Where primers were included 10 pmoles each of GH15 (SEQ ID NO: 3) and GH16 (SEQ ID NO: 4) were added. Reaction mixtures 1 and 2 were not subjected to amplification cycles. Reactions Nos. 3, 4, and 5 were subjected to 20 cycles of amplification. The cycling parameters were 94°C, hold for 1 minute; 45°C, hold for 1 minute; and 72°C, hold for 1 minute.

10 **[0099]** The reaction tubes were then placed on a UV light box (300 nm) and photographed for two seconds and one-half second exposures. The results, shown in Figure 1, demonstrated the increased fluorescence in Reaction No. 3 due to the amplification of the specific target DNA. Reaction Nos. 1 and 2 indicated the level of fluorescence present before any amplification occurred. Reaction Nos. 4 and 5 demonstrated that fluorescence does not increase visibly in a reaction unless, for the particular primer pair present in the reaction, an appropriate template is also present. The different photographic exposures as shown in Figure 1 demonstrate the relative differences in fluorescence.

15 Example III

[0100] The ability of the present homogeneous assay method for detecting a specific target in the presence of non-target double-stranded DNA was tested. This example demonstrates detection of a specific DNA sequence in a background of genomic DNA. Twenty 100 μ l PCR mixtures were prepared as follows. Each contained 10 mM TrisHCl, pH 8; 50 mM KCl; 2 mM MgCl₂; 2.9 units Taq polymerase; 180 μ M each dNTP; 1.27 μ M ethidium bromide; 15 picomole RH191 (SEQ ID NO: 7); and 15 picomole RH192 (SEQ ID NO: 8). The primers RH191 (SEQ ID NO: 7) and RH192 (SEQ ID NO: 8) are derived from primers yl.1 and yl.2, which are described in Kogan et al., 1987, N. Engl. J. Med., 317:985-990. These primers are specific for a human male-specific sequence that occurs in several thousand copies per human male cell. Fifteen PCR reaction mixtures were set up as follows. Sample DNA was prepared from human blood taken from a male or female as specified for each reaction. DNA was prepared according to Maniatis supra.

Reaction Nos. 1-5 contained 2 ng human male DNA

Reaction Nos. 6-10 contained no DNA

30 Reaction Nos. 11-15 contained 60 ng human female DNA

Reaction Nos. 16-20 contained 60 ng human male DNA

The reactions were all placed in a Perkin-Elmer Cetus Instruments thermocycler programmed to cycle at 94°C for 1 minute; 60°C for 1 minute, for the indicated number of cycles. As indicated below, tubes were removed from the thermocycler at various cycles to provide a PCR time course for each template. Specifically, for each set of five tubes, 0, 17, 21, 25, and 29 amplification cycles were performed. PCR product was detected by exposing the tubes to UV-light as described above.

40 **[0101]** By photography and visual inspection, Tube Nos. 6-15 exhibited no increase in fluorescence. Tube Nos. 1 and 2, the 0 and 17 cycle male DNA samples, also had no increase in fluorescence by visual detection. Only the 21, 25, and 29 cycle male DNA reactions fluoresced under UV light, and the amount of fluorescence increased with increasing cycle number. The results with Tube Nos. 16-20 were similar, except that an increase in fluorescence was noted by 17 cycles. This is consistent with the presence of more copies of the target DNA sequence present in the sample prior to amplification.

45 Example IV

[0102] For quantitative measurement of target specific ethidium bromide fluorescence the reactions of Example III were opened, and the contents transferred to a spectra fluorometer (SPEX Fluorolog-2, purchased from Spex, Edison, NJ) which was used to get a quantitative fluorescence value for each reaction. The results shown in Figure 2 not only demonstrate the target specificity of the detection method but illustrate the quantitative aspects of the invention. The effect of increased target in the sample is observable by comparing the time course of fluorescence between the 2 ng and 60 ng male templates. The more target DNA in the sample, the sooner the reaction obtains a measurable increase in fluorescence and finally reaches a plateau level of fluorescence. Exactly when the reaction fluorescence begins to increase measurably is effectively a quantitative measure of how much target was present prior to amplification.

55 Example V

[0103] This example demonstrates the suitability of the homogeneous assay not only for detecting a single copy

gene among total human genomic DNA, but for discriminating among two alleles of that single copy gene present in the sample that differ by a single nucleotide. (Methods for allele specific detection are described in detail in European Patent Publication No. 237,362, which is incorporated herein by reference).

[0104] The particular gene to be detected is the β -globin gene. A single base pair change mutates a wild-type β -globin allele into a sickle cell allele. In this example, the following primers were used: RH187 (SEQ ID NO: 9), RH188 (SEQ ID NO: 10), and RH189 (SEQ ID NO: 11). Primer pair RH187/RH188 (SEQ ID NO: 9/SEQ ID NO: 10) specifically amplified the wild-type allele. Primer pair RH187/RH189 (SEQ ID NO: 9/SEQ ID NO: 11) amplify the sickle cell allele (these primers derive from BGP2, H β 14A, and H β 14S described in Wu et al., 1989, PNAS (USA), 86:27572760. Six PCR's were set up as follows: 10 mM Tris-HCl, pH 8.3; 50 mM KCl; 748 μ M total dNTPs; 2.9 units Taq polymerase; 10 pmols each primer; 1.5 μ M MgCl₂; 1.27 μ M ethidium bromide, and 50 ng of human DNA template as follows: one pair of reactions contained human DNA homozygous for sickle allele (SS); one pair of reactions contained wild-type DNA (AA); and one pair contained heterozygous DNA, i.e., one wild-type and one sickle cell allele (AS).

[0105] For each pair of reactions, one tube contained primers specific for the sickle globin allele and one tube contained primers for the wild-type sequence. The only difference between the primer sets are the 3' nucleotides of one of the primer pairs, which match either the sickle cell or the wild-type target sequence. Primer annealing temperature during PCR is set such that amplification will occur only if this 3' nucleotide matches the template. The cycling parameters were: 94°C for 60 seconds, 55°C for 60 seconds.

[0106] The reaction was done in triplicate and after 30 cycles of PCR, the tubes were placed on a UV-light source and photographed. The photographs are shown in Figure 3. The results were as follows:

	Sickle β -globin Primers	Wild-type Primers
Homozygous AA	-	+
Heterozygous AS	+	+
Homozygous SS	+	-

A "+" indicates that fluorescence was readily visible under UV light, and when measured on a spectra-fluorometer the "+" tubes had approximately three times greater fluorescence than "-" reactions. The PCR's marked "-" did not change significantly in fluorescence as a result of the amplification reaction.

[0107] Aliquots of each reaction were analyzed by gel electrophoresis. Each "+" reaction exhibited a specific discrete DNA fragment. The "-" reactions had no such DNA fragment by gel analysis.

Example VI

[0108] A detection assay was designed to demonstrate the suitability of the present invention for detecting a rare target sequence in a background of DNA from approximately 70,000 human cells. A modified nested primer procedure, as briefly described in the "Detailed Description" section as a primer "drop-out" procedure, was designed to enhance PCR specificity. This assay was done as follows: into PCR reaction vessels 1 through 8 were aliquoted 50 microliters of solution, each containing 50 mM KCl; 10 mM TrisHCl, pH 8.3; 2.5 mM MgCl₂; 600 μ M total dNTPs; 1.25 unit of Taq DNA polymerase (PECI); 1.27 μ M ethidium bromide; 0.5 μ g of human cell-line DNA; the primer pair RH171 (SEQ ID NO: 12) and RH176 (SEQ ID NO: 13), each primer at 0.2 μ M; and the nested primer RH182 (SEQ ID NO: 14) also at 0.2 μ M. A drop of mineral oil was used to cover the eight solutions in order to prevent evaporation. Primer RH176 (SEQ ID NO: 13) carries a GC-rich, non-homologous (to target sequence), 5' "tail" that raises the denaturation temperature necessary to amplify PCR product made using this primer.

[0109] Reactions 1-4 were made with solutions that were at ambient room temperature and included the three primers before temperature cycling was begun. Reactions 5-8 were made with the addition of the three primers postponed until these reactions were equilibrated to a temperature of 72°C before beginning thermocycling. For this reason, reactions 5-8 are referred to as being given a "hot-start." Reactions 2-4 and 6-8 also contained a target, positive control DNA (purchased from PECl) containing HIV sequences to which RH171 (SEQ ID NO: 12), RH176 (SEQ ID NO: 13), and the 3' portion of RH182 (SEQ ID NO: 14) were homologous. This DNA was diluted such that each reaction containing it had, on average, four copies of the HIV sequence. Because this average number of copies is small, the actual number of copies in a given reaction can vary considerably. Since no HIV DNA target was added to reactions 1 and 5, these reactions served as negative controls.

[0110] All eight reactions were subjected to thermocycling as follows: denature at 96°C, hold for 1 minute, anneal at 64°C, hold for 1 minute. This profile was repeated for 29 cycles, during which the flanking primer pair, RH171 (SEQ ID NO: 12) and RH176 (SEQ ID NO: 13), efficiently annealed and were used in amplification, while the nested primer RH182 (SEQ ID NO: 14), which does not efficiently anneal at 64°C, was not used in efficient amplification. This was followed by denaturation at 96°C, hold for 1 minute, annealing at 52°C, hold for 1 minute. This profile was repeated

for 2 cycles, during which all three primers efficiently annealed and were extended in amplification such that products were made using either RH171 (SEQ ID NO: 12) and RH176 (SEQ ID NO: 13), or RH171 (SEQ ID NO: 12) and RH182 (SEQ ID NO: 14). Because the use of a third, nested primer, increases product specificity, products made using RH171 (SEQ ID NO: 12) and RH182 (SEQ ID NO: 14) were more likely to be HIV specific. These cycles were followed by denaturation at 86°C, hold for 1 minute, anneal at 52°C, hold for 1 minute. This profile was repeated 18 times, during which, products that included the GC-rich primer RH176 (SEQ ID NO: 13), both HIV specific and non-specific, did not efficiently denature at 86°C and, therefore, did not amplify efficiently, while the amplified HIV sequences made using the nested primer RH182 (SEQ ID NO: 14) and RH171 (SEQ ID NO: 12) did efficiently denature and amplify.

[0111] All eight reactions were analyzed, when completed, by gel electrophoresis. Reactions 2-4 and 5-8 were shown to contain a product of the expected size (approximately 200 bp) as the predominant band on the gel. Reactions 1 and 5, the negative controls, contained no such product. However, reactions 2-4, which were not given a "hot-start," could be seen to contain DNA fragments of other than the expected size. These other DNA fragments were also visible in reaction 1, indicating that they are not derived from HIV sequences. These other DNA fragments were not visible in reactions 5-8, indicating that use of the "hot-start" had enhanced the specificity of these reactions.

[0112] Eight additional reactions were performed as described above, except that all were given a "hot-start" as described above. The positive control DNA was diluted in these eight reactions, numbered 1 through 8, such that on average, each contains half an HIV target molecule. Since a molecule cannot be divided, this means that some reactions should contain a target molecule and some should not. If this experiment were repeated many times, the fraction of reactions that do contain a target will vary considerably, but should be on average about half. Those that do contain a target molecule are most likely to contain a single target molecule. Upon completion of the reactions, all eight were analyzed by gel electrophoresis. The result was that two of the eight reactions, numbers 1 and 8, displayed a DNA fragment of the expected size (approximately 200 bp) as the predominant band on the gel, with no other bands that migrated into the gel visible except a band corresponding to the primers. Reactions 2-6 displayed no such bands nor any other DNA fragment bands.

Example VII

[0113] For quantitative detection of the PCR product a spectra-fluorometer Spex fluorolog-2 (Spex, Edison, NJ) was used to quantitate the net increase in fluorescence generated in response to what is expected to be a single HIV target in the presence of genomic DNA. The spectra-fluorometer was used according to manufacture's specifications as described in Example VIII. The PCR reactions described in Example VI, in which positive control DNA was diluted among eight reactions to contain half an HIV target molecule per reaction, were analyzed for their fluorescence. Twenty μ l of each completed reaction was added to 100 μ l of 10 mM Tris HCl, pH 8, 0.1 mM EDTA, 1.27 pM ethidium bromide. The fluorescence of these solutions was measured at 570 nm. Figure 4A graphically demonstrates the significant increase in fluorescence of the two positive samples compared to the two negative samples. In the figure, dotted lines mark the fluorescence values two standard deviations away from the average of the negative samples. The PCR-positive samples are both above this line.

[0114] The results are also shown in Figure 4B using a background subtraction method. The fluorescence up to the second standard deviation below the mean was subtracted from the detected values. Background subtraction is preferably performed by measuring fluorescence in each sample at the beginning of PCR cycling (preferably after the initial denaturation, which reduces the proportion of double-stranded genomic DNA) and subtracting that value from the fluorescence in the sample at the end of PCR cycling.

Example VIII

[0115] The following experiment demonstrates the suitability of the present method for monitoring a PCR reaction and detecting the net increase in double-stranded DNA due to amplification. The apparatus allows on-line detection of PCR product.

[0116] The apparatus was set up as follows: a Spex-Fluorolog-2 fluorometer with a fiber optic accessory (Spex Catalog No. 1950) was set to emit excitation light at 500 nm with a bandwidth of \sim 3.4 nm. A GG 435 nm cut off filter used to exclude second order light (Purchased from Melles Griest Inc.). The emission light was detected at 570 nm with a bandwidth of \sim 13.6 nm. A OG530 filter (530 nm cut off) was used to remove excitation light.

[0117] Two PCR reactions were set up as described in Example III using primers RH191 (SEQ ID NO: 7) and RH192 (SEQ ID NO: 8). One reaction tube contained 60 ng human male DNA, the other contained no target DNA. The reactions were set up in 0.5 ml polypropylene tubes; however, the top of the tubes was cut away for attaching the fiber optic cable. The fiber optic was glued to the top of the reaction tube with epoxy. Because this apparatus had one fiber optic, only one PCR was run at a time. The emission light was collected through the oil overlay in the tube. A black "shroud" was built around the tube and the reaction was placed in the thermocycler. The thermocycler was programmed to cycle

between 94°C and 50°C for 1 minute each, for 30 cycles, followed by continuous incubation at 25°C. The fluorometer and thermocycler were started simultaneously. The parameters of the fluorometer were: time based scan with 5 second integration time; the emission signal was ratioed to that of the excitation light to control for changes in source intensity.

[0118] Figure 5A shows the results of the PCR reaction containing no DNA. Figure 5A shows that the thermocycler started at 25°C, the fluorescence dropped as the temperature increased to 94°C and fluorescence increased again when the temperature decreased to 50°C. This pattern was repeated for the remaining cycles until the thermocycler again reached 25°C and the fluorescence returned to the approximate starting value.

[0119] Figure 5B demonstrates the fluorescence profile of a PCR reaction containing the appropriate target DNA. The fluorescence intensity at 50°C shows a cycle dependent increase reflecting an increase in the amount of double-stranded DNA. When the thermocycler returned to 25°C, after the 30 cycles were completed, the fluorescence increased to a final value greater than three times the initial fluorescence value at 25°C.

[0120] Following amplification, an aliquot of each reaction mixture was analyzed by agarose gel electrophoresis. The gel analysis demonstrated that no PCR product was visible in the lane containing a sample from the negative control. The electrophoresed sample from the positive control PCR showed a clear and unique band at ~150 base pairs. The predicted size of the PCR product was 154 bp.

[0121] Thus, the on-line method provided a rapid analysis as to the presence or absence of target DNA without the need for probes or further processing steps. In addition, the continuous detection of fluorescence throughout the amplification provides an amplification profile that reflects the amount of target present at start. If the target DNA is, for example, a human repeat sequence present in millions of copies per cell (e.g., "Alu" sequences; Nelson and Caskey in PCR Technology ed. Erlich, 1989, Stockton Press, NY), this method of quantitation could be used to quickly and simply to measure subcellular amounts of DNA, which is at present difficult to do without using radioisotopes.

Primer Sequences for Examples I-VIII

<u>Ref.-No.</u>	<u>SEQ ID NO</u>	<u>Primer Sequence</u>
GH26	1	5' GTGCTGCAGG TGTAACCTTG TACCAG 3'
GH27	2	5' CACGGATCCG GTAGCAGCGG TAGAGTTG 3'
GH15	3	5' GTGTAAACTT GTACCAG 3'
GH16	4	5' GGTCAGCAGCG GTAGAG 3'
GH46	5	5' CCGGATCCTT CGTGTCCCCA CAGCAGC 3'
GH50	6	5' CTCCCCAACC CCGTAGTTGT GTCTGCA 3'
RH191	7	5' TCCACTTTAT TCCAGGCCTG T 3'
RH192	8	5' TTGAATGGAA TGGGAACGAA TGG 3'
RH187	9	5' AATAGACCAA TAGGCAGAG 3'
RH188	10	5' CACCTGACTC CTGA 3'
RH189	11	5' CACCTGACTC CTGT 3'
RH171	12	5' CCAGGCCAGA TGAGAGAACC AAGGGG 3'
RH176	13	5' GCGGGCAGGG CGGCGGGGGC GGGGCCGAAC CGGTCTACAT AGTCTCTAAA GGG 3'
RH182	14	5' GGTCCCTGTC TTATGTC 3'

SEQUENCE LISTING

[0122]

- INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

10

GTGCTGCAGG TGTAAGCTTG TACCAG

26

- INFORMATION FOR SEQ ID NO:2:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

25

CACGGATCCG GTAGCAGCGG TAGAGTTG

28

- INFORMATION FOR SEQ ID NO:3:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

40

GTGTAACTT GTACCAG

17

45

- INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

55

GGTAGCAGCG GTAGAG

16

- INFORMATION FOR SEQ ID NO:5:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

10

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGGATCCTT CGTGTCCCCA CAGCACG

27

20

- INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTCCCCAACC CCGTAGTTGT GTCTGCA

27

35

- INFORMATION FOR SEQ ID NO:7:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

45

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

50

TCCACTTTAT TCCAGGCCTG T

21

55

- INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

10

TTGAATGGAA TGGGAACGAA TGG

23

- INFORMATION FOR SEQ ID NO:9:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA (genomic)

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AATAGACCAA TAGGCAGAG

19

30 - INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA (genomic)

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CACCTGACTC CTGA

14

45

- INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: DNA (genomic)

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CACCTGACTC CTGT

14

- INFORMATION FOR SEQ ID NO:12:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid

10

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCAGGCCAGA TGAGAGAACC AAGGGG

26

20 - INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 base pairs

25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCGGGCAGGG CGGCGGGGGC GGGGCCGAAC CGGTCTACAT AGTCTCTAAA GGG 53

35

- INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

50

GGTCCCTGTC TTATGTC

17

55

Claims

Claims for the following Contracting States : AT, BE, CH, DK, ES, LI, NL, SE

5

1. A method for detecting a target nucleic acid in a sample, said method comprises the steps of:

10

(a) providing an amplification reaction mixture that comprises said sample, a DNA binding agent, wherein said agent is characterized as providing a detectable signal when bound to double-stranded nucleic acid which signal is distinguishable from the signal provided by said agent when it is unbound, and reagents for amplification;

15

(b) determining the amount of said signal produced by the mixture of step (a);

(c) treating said mixture under conditions for amplifying said target nucleic acid;

(d) determining the amount of said signal produced by said mixture of step (c); and

20

(e) determining if amplification has occurred.

2. Method of claim 1, wherein said DNA binding agent is further characterized as providing an amount of detectable signal when said agent is bound to double-stranded nucleic acids that is greater than the amount of said detectable signal produced when said agent is unbound.

25

3. Method of claim 1 or 2, wherein said DNA binding agent is an intercalating agent.

4. Method of claim 3, wherein said intercalating agent is a fluorescent dye.

30

5. Method of claim 4, wherein at step (e) an increase in fluorescence indicates that amplification has occurred.

6. Method of claim 5, wherein at steps (b) and (d) the amount of signal produced is determined by exposing said mixture to UV light, and at step (e) comparing the relative amount of signal produced at steps (b) and (d) to determine if amplification has occurred.

35

7. Method of any one of claims 4-6, wherein said fluorescent dye is ethidium bromide.

8. Method of any one of claims 4-7, wherein the amount of signal produced is determined using a spectra fluorometer.

40

9. Method of any one of claims 5-8, wherein the amount of target DNA in said sample, prior to amplification, is quantitated by determining the increase in fluorescence before and after amplification.

10. Method of any one of claims 1-9, wherein said target nucleic acid is indicative of a genetic or infectious disease.

45

11. A method for monitoring the increase in double-stranded DNA during amplification of a target nucleic acid in a sample, said method comprises the steps of:

50

(a) providing an amplification reaction mixture that comprises said sample and a DNA binding agent, wherein said agent is characterized as providing a detectable signal when bound to double-stranded nucleic acid which signal is distinguishable from the signal provided by said agent when it is unbound;

(b) determining the amount of said signal produced by the mixture of step (a);

(c) treating said mixture under conditions for amplifying said target nucleic acid; and

55

(d) determining during said amplification step (c) the amount of said signal produced by said amplification reaction mixture.

12. Method of claim 11, wherein at steps (b) and (d), an optic fiber and spectra fluorometer are used to determine the

amount of signal produced during said treating step.

13. Method of claim 11 or 12, wherein at step (d) the amount of signal is determined continuously throughout amplification reaction.

14. Method of any one of claims 11-13, wherein said DNA binding agent is an intercalating agent.

15. Method of claim 14, wherein said intercalating agent is a fluorescent dye.

16. Method of claim 15, wherein said fluorescent dye is ethidium bromide.

17. Method of any one of claims 1-16, wherein said amplification reaction is a polymerase chain reaction (PCR).

18. A method according to any one of claims 1-17, wherein the amount of the target nucleic acid in the sample is quantitated.

19. A kit for amplifying a target nucleic acid, that kit comprising an amplification mixture for an amplification reaction and an intercalating agent provided that said mixture does not contain either a polymerase or primers together.

20. Kit of claim 19, wherein said intercalating agent is a fluorescent dye.

21. Kit of claim 20, wherein said fluorescent dye is ethidium bromide.

22. Kit of any one of claims 19-21, wherein said amplification mixture is a PCR buffer.

23. Kit of claim 22, wherein said ethidium bromide is present at a concentration suitable to provide between 0.15 μM and 40.6 μM dye in a PCR reaction.

24. Kit of claim 22 or 23, wherein said amplification mixture also comprises Tris-HCl, pH 8.0-8.3 and KCl, each present in a concentration suitable for amplifying a target nucleic acid in a PCR.

25. Kit of any one of claims 19-23 that also comprises a DNA polymerase, MgCl_2 , and dNTPs.

Claims for the following Contracting States : DE, FR, GB, IT

1. A method for detecting a target nucleic acid in a sample, said method comprises the steps of:

(a) providing an amplification reaction mixture that comprises said sample, a DNA binding agent, wherein said agent is characterized as providing an optically detectable signal when bound to double-stranded nucleic acid which signal is distinguishable from the signal provided by said agent when it is unbound, and reagents for amplification;

(b) determining the amount of said signal produced by the mixture of step (a) by a fiber optic;

(c) treating said mixture under conditions for amplifying said target nucleic acid;

(d) determining the amount of said signal produced by said mixture of step (c) by said fiber optic; and

(e) determining if amplification has occurred.

2. Method of claim 1, wherein said DNA binding agent is further characterized as providing an amount of detectable signal when said agent is bound to double-stranded nucleic acids that is greater than the amount of said detectable signal produced when said agent is unbound.

3. Method of claim 1 or 2, wherein said DNA binding agent is an intercalating agent.

4. Method of claim 3, wherein said intercalating agent is a fluorescent dye.

5. Method of claim 4, wherein at step (e) an increase in fluorescence indicates that amplification has occurred.
6. Method of claim 5, wherein at steps (b) and (d) the amount of signal produced is determined by exposing said mixture to UV light, and at step (e) comparing the relative amount of signal produced at steps (b) and (d) to determine if amplification has occurred.
7. Method of any one of claims 4-6, wherein said fluorescent dye is ethidium bromide.
8. Method of any one of claims 4-7, wherein the amount of signal produced is determined using a spectra fluorometer.
9. Method of any one of claims 5-8, wherein the amount of target DNA in said sample, prior to amplification, is quantitated by determining the increase in fluorescence before and after amplification.
10. Method of any one of claims 1-9, wherein said target nucleic acid is indicative of a genetic or infectious disease.
11. A method for monitoring the increase in double-stranded DNA during amplification of a target nucleic acid in a sample, said method comprises the steps of:
 - (a) providing an amplification reaction mixture that comprises said sample and a DNA binding agent, wherein said agent is characterized as providing a detectable signal when bound to double-stranded nucleic acid which signal is distinguishable from the signal provided by said agent when it is unbound;
 - (b) determining the amount of said signal produced by the mixture of step (a);
 - (c) treating said mixture under conditions for amplifying said target nucleic acid; and
 - (d) determining during said amplification step (c) the amount of said signal produced by said amplification reaction mixture .
12. Method of claim 11, wherein at steps (b) and (d), an optic fiber and spectra fluorometer are used to determine the amount of signal produced during said treating step.
13. Method of claim 11 or 12, wherein at step (d) the amount of signal is determined continuously throughout amplification reaction.
14. Method of any one of claims 11-13, wherein said DNA binding agent is an intercalating agent.
15. Method of claim 14, wherein said intercalating agent is a fluorescent dye.
16. Method of claim 15, wherein said fluorescent dye is ethidium bromide.
17. Method of any one of claims 1-16, wherein said amplification reaction is a polymerase chain reaction (PCR).
18. A method according to any one of claims 1-17, wherein the amount of the target nucleic acid in the sample is quantitated.
19. A kit for amplifying a target nucleic acid, that kit comprising an amplification mixture for an amplification reaction and an intercalating agent provided that said mixture does not contain either a polymerase or primers together.
20. Kit of claim 19, wherein said intercalating agent is a fluorescent dye.
21. Kit of claim 120, wherein said fluorescent dye is ethidium bromide.
22. Kit of any one of claims 19-21, wherein said amplification mixture is a PCR buffer.
23. Kit of claim 22, wherein said ethidium bromide is present at a concentration suitable to provide between 0.15 μ M and 40.6 μ M dye in a PCR reaction.

24. Kit of claim 22 or 23, wherein said amplification mixture also comprises Tris-HCl having a pH 8.0-8.3 and KCl, each present in a concentration suitable for amplifying a target nucleic acid in a PCR.
25. Kit of any one of claims 19-23 that also comprises a DNA polymerase, $MgCl_2$, and dNTPs:

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DK, ES, LI, NL, SE

1. Verfahren zum Nachweis einer Zielnucleinsäure in einer Probe, wobei das Verfahren folgende Schritte umfaßt:
 - (a) Bereitstellung eines Amplifikationsreaktionsgemisches, das die Probe, ein DNA-Bindemittel, wobei das Mittel dadurch gekennzeichnet ist, daß es ein nachweisbares Signal liefert, wenn es an eine doppelsträngige Nucleinsäure gebunden ist, wobei das Signal unterscheidbar ist von einem Signal, das durch das Mittel geliefert wird, wenn es nicht gebunden ist, und Reagenzien für die Amplifikation umfaßt;
 - (b) Bestimmung der Menge des Signales, das durch das Gemisch von Schritt (a) produziert wird;
 - (c) Behandlung des Gemisches unter Bedingungen für die Amplifikation der Zielnucleinsäure;
 - (d) Bestimmung der Menge des Signals, das von dem Gemisch von Schritt (c) produziert wird; und
 - (e) Bestimmung, ob Amplifikation stattgefunden hat.
2. Verfahren nach Anspruch 1, wobei das DNA-Bindemittel ferner dadurch charakterisiert ist, daß es eine Menge des nachweisbaren Signals liefert, wenn das Mittel an die doppelsträngigen Nucleinsäuren gebunden ist, die größer ist als die Menge des nachweisbaren Signals, die produziert wird, wenn das Mittel nicht gebunden ist.
3. Verfahren nach Anspruch 1 oder 2, wobei das DNA-Bindemittel ein intercalierendes Mittel ist.
4. Verfahren nach Anspruch 3, wobei das intercalierende Mittel ein Fluoreszenzfarbstoff ist.
5. Verfahren nach Anspruch 4, wobei bei Schritt (e) ein Anstieg der Fluoreszenz anzeigt, daß Amplifikation stattgefunden hat.
6. Verfahren nach Anspruch 5, wobei bei den Schritten (b) und (d) die Menge des produzierten Signals dadurch bestimmt wird, daß das Gemisch UV-Licht ausgesetzt wird, und bei Schritt (e) die relative Menge des Signals verglichen wird, das bei den Schritten (b) und (d) produziert wurde, um zu bestimmen, ob Amplifikation stattgefunden hat.
7. Verfahren nach einem der Ansprüche 4 bis 6, wobei der Fluoreszenzfarbstoff Ethidiumbromid ist.
8. Verfahren nach einem der Ansprüche 4 bis 7, wobei die Menge des produzierten Signals unter Verwendung eines Spektralfluorometers bestimmt wird.
9. Verfahren nach einem der Ansprüche 5 bis 8, wobei die Menge der Ziel-DNA in der Probe vor der Amplifikation quantifiziert wird, indem der Anstieg der Fluoreszenz vor und nach der Amplifikation bestimmt wird.
10. Verfahren nach einem der Ansprüche 1 bis 9, wobei die Zielnucleinsäure als Hinweis auf eine genetische oder infektiöse Krankheit dient.
11. Verfahren zum Aufzeichnen des Anstiegs der doppelsträngigen DNA während der Amplifikation einer Zielnucleinsäure in einer Probe, wobei das Verfahren folgende Schritte umfaßt:
 - (a) Bereitstellen eines Amplifikationsreaktionsgemisches, das die Probe und ein DNA-Bindemittel umfaßt, wobei das Mittel dadurch gekennzeichnet ist, daß es ein nachweisbares Signal liefert, wenn es an doppelsträngige Nucleinsäure gebunden ist, wobei das Signal unterscheidbar ist von dem Signal, das von dem Mittel geliefert wird, wenn es nicht gebunden ist;
 - (b) Bestimmung der Menge des Signals, das von dem Gemisch von Schritt (a) produziert wird;
 - (c) Behandlung des Gemisches unter Bedingungen für die Amplifikation der Zielnucleinsäure; und

(d) Bestimmung während des Amplifikationsschrittes (c) der Menge an Signal, das von dem Amplifikationsreaktionsgemisch produziert wird.

12. Verfahren nach Anspruch 11, wobei bei den Schritten (b) und (d) eine Faseroptik und ein Spektralfluorometer verwendet werden, um die Menge des während des Behandlungsschrittes produzierten Signals zu bestimmen.
13. Verfahren nach Anspruch 11 oder 12, wobei bei Schritt (d) die Menge des Signals kontinuierlich während der Amplifikationsreaktion bestimmt wird.
14. Verfahren nach einem der Ansprüche 11 bis 13, wobei das DNA-Bindemittel ein intercalierendes Mittel ist.
15. Verfahren nach Anspruch 14, wobei das intercalierende Mittel ein Fluoreszenzfarbstoff ist.
16. Verfahren nach Anspruch 15, wobei der Fluoreszenzfarbstoff Ethidiumbromid ist.
17. Verfahren nach einem der Ansprüche 1 bis 16, wobei die Amplifikationsreaktion eine Polymerasekettenreaktion (PCR) ist.
18. Verfahren nach einem der Ansprüche 1 bis 17, wobei die Menge der Zielnucleinsäure in der Probe quantifiziert wird.
19. Kit für die Amplifikation einer Zielnucleinsäure, wobei der Kit ein Amplifikationsgemisch für eine Amplifikationsreaktion und ein intercalierendes Mittel umfaßt, mit der Maßgabe, daß das Gemisch eine Polymerase oder Primer nicht zusammen enthält.
20. Kit nach Anspruch 19, wobei das intercalierende Mittel ein Fluoreszenzfarbstoff ist.
21. Kit nach Anspruch 20, wobei der Fluoreszenzfarbstoff Ethidiumbromid ist.
22. Kit nach einem der Ansprüche 19 bis 21, wobei das Amplifikationsgemisch ein PCR-Puffer ist.
23. Kit nach Anspruch 22, wobei das Ethidiumbromid in einer Konzentration vorliegt, die geeignet ist, 0,15 µM und 40,6 µM Farbstoff in einer bereitzustellen.
24. Kit nach Anspruch 22 oder 23, wobei das Amplifikationsgemisch auch Tris-HCl mit einem pH-Wert von 8,0 bis 8,3 und KCl enthält, wobei beide Bestandteile in einer Konzentration vorliegen, die für die Amplifikation einer Zielnucleinsäure in einer PCR geeignet ist.
25. Kit nach einem der Ansprüche 19 bis 23, der ferner eine DNA-Polymerase, MgCl₂ und dNTPs enthält.

Patentansprüche für folgende Vertragsstaaten : DE, FR, GB, IT

1. Verfahren zum Nachweis einer Zielnucleinsäure in einer Probe, wobei das Verfahren folgende Schritte umfaßt:
 - (a) Bereitstellung eines Amplifikationsreaktionsgemisches, das die Probe, ein DNA-Bindemittel, wobei das Mittel dadurch gekennzeichnet ist, daß es ein optisch nachweisbares Signal liefert, wenn es an eine doppelsträngige Nucleinsäure gebunden ist, wobei das Signal unterscheidbar ist von einem Signal, das durch das Mittel geliefert wird, wenn es nicht gebunden ist, und Reagenzien für die Amplifikation umfaßt;
 - (b) Bestimmung der Menge des Signales, das durch das Gemisch von Schritt a) produziert wird, mit einer Faseroptik; und
 - (c) Behandlung des Gemisches unter Bedingungen für die Amplifikation der Zielnucleinsäure;
 - (d) Bestimmung der Menge des Signals, das von dem Gemisch von Schritt (c) produziert wird, mit der Faseroptik; und
 - (e) Bestimmung, ob Amplifikation stattgefunden hat.
2. Verfahren nach Anspruch 1, wobei das DNA-Bindemittel ferner dadurch charakterisiert ist, daß es eine Menge des nachweisbaren Signals liefert, wenn das Mittel an die doppelsträngigen Nucleinsäuren gebunden ist, die größer ist als die Menge des nachweisbaren Signals, die produziert wird, wenn das Mittel nicht gebunden ist.

3. Verfahren nach Anspruch 1 oder 2, wobei das DNA-Bindemittel ein intercalierendes Mittel ist.
4. Verfahren nach Anspruch 3, wobei das intercalierende Mittel ein Fluoreszenzfarbstoff ist.
- 5 5. Verfahren nach Anspruch 4, wobei bei Schritt (e) ein Anstieg der Fluoreszenz anzeigt, daß Amplifikation stattgefunden hat.
6. Verfahren nach Anspruch 5, wobei bei den Schritten (b) und (d) die Menge des produzierten Signals dadurch bestimmt wird, daß das Gemisch UV-Licht ausgesetzt wird, und bei Schritt (e) die relative Menge des Signals
10 verglichen wird, das bei den Schritten (b) und (d) produziert wurde, um zu bestimmen, ob Amplifikation stattgefunden hat.
7. Verfahren nach einem der Ansprüche 4 bis 6, wobei der Fluoreszenzfarbstoff Ethidiumbromid ist.
- 15 8. Verfahren nach einem der Ansprüche 4 bis 7, wobei die Menge des produzierten Signals unter Verwendung eines Spektralfluorometers bestimmt wird.
9. Verfahren nach einem der Ansprüche 5 bis 8, wobei die Menge der Ziel-DNA in der Probe vor der Amplifikation quantifiziert wird, indem der Anstieg der Fluoreszenz vor und nach der Amplifikation bestimmt wird.
- 20 10. Verfahren nach einem der Ansprüche 1 bis 9, wobei die Zielnucleinsäure als Hinweis auf eine genetische oder infektiöse Krankheit dient.
- 25 11. Verfahren zum Aufzeichnen des Anstiegs der doppelsträngigen DNA während der Amplifikation einer Zielnucleinsäure in einer Probe, wobei das Verfahren folgende Schritte umfaßt:
 - (a) Bereitstellen eines Amplifikationsreaktionsgemisches, das die Probe und ein DNA-Bindemittel umfaßt, wobei das Mittel dadurch gekennzeichnet ist, daß es ein nachweisbares Signal liefert, wenn es an doppelsträngige Nucleinsäure gebunden ist, wobei das Signal unterscheidbar ist von dem Signal, das von dem Mittel
30 geliefert wird, wenn es nicht gebunden ist;
 - (b) Bestimmung der Menge des Signals, das von dem Gemisch von Schritt (a) produziert wird;
 - (c) Behandlung des Gemisches unter Bedingungen für die Amplifikation der Zielnucleinsäure; und
 - (d) Bestimmung während des Amplifikationsschrittes (c) der Menge an Signal, das von dem Amplifikationsreaktionsgemisch produziert wird.
- 35 12. Verfahren nach Anspruch 11, wobei bei den Schritten (b) und (d) eine Faseroptik und ein Spektralfluorometer verwendet werden, um die Menge des während des Behandlungsschrittes produzierten Signals zu bestimmen.
- 40 13. Verfahren nach Anspruch 11 oder 12, wobei bei Schritt (d) die Menge des Signals kontinuierlich während der Amplifikationsreaktion bestimmt wird.
14. Verfahren nach einem der Ansprüche 11 bis 13, wobei das DNA-Bindemittel ein intercalierendes Mittel ist.
- 45 15. Verfahren nach Anspruch 14, wobei das intercalierende Mittel ein Fluoreszenzfarbstoff ist.
16. Verfahren nach Anspruch 15, wobei der Fluoreszenzfarbstoff Ethidiumbromid ist.
17. Verfahren nach einem der Ansprüche 1 bis 16, wobei die Amplifikationsreaktion eine Polymerasekettenreaktion (PCR) ist.
- 50 18. Verfahren nach einem der Ansprüche 1 bis 17, wobei die Menge der Zielnucleinsäure in der Probe quantifiziert wird.
19. Kit für die Amplifikation einer Zielnucleinsäure, wobei der Kit ein Amplifikationsgemisch für eine Amplifikationsreaktion und ein intercalierendes Mittel umfaßt, mit der Maßgabe, daß das Gemisch eine Polymerase oder Primer
55 nicht zusammen enthält.
20. Kit nach Anspruch 19, wobei das intercalierende Mittel ein Fluoreszenzfarbstoff ist.

21. Kit nach Anspruch 20, wobei der Fluoreszenzfarbstoff Ethidiumbromid ist.
22. Kit nach einem der Ansprüche 19 bis 21, wobei das Amplifikationsgemisch ein PCR-Puffer ist.
- 5 23. Kit nach Anspruch 22, wobei das Ethidiumbromid in einer Konzentration vorliegt, die geeignet ist, um zwischen 0,15 μM und 40,6 μM Farbstoff in einer PCR-Reaktion bereitzustellen.
24. Kit nach Anspruch 22 oder 23, wobei das Amplifikationsgemisch auch Tris-HCl mit einem pH-Wert von 8,0 bis 8,3 und KCl enthält, wobei beide Bestandteile in einer Konzentration vorliegen, die für die Amplifikation einer Zielnu-
cleinsäure in einer PCR geeignet ist.
- 10 25. Kit nach einem der Ansprüche 19 bis 23, der ferner eine DNA-Polymerase, MgCl_2 und dNTPs enthält.

15 **Revendications**

Revendications pour les Etats contractants suivants : AT, BE, CH, DK, ES, LI, NL, SE

- 20 1. Procédé pour détecter un acide nucléique cible dans un échantillon, ledit procédé comprenant les étapes consistant :
- (a) à mettre à disposition un mélange pour réaction d'amplification qui comprend ledit échantillon, un agent de liaison à l'ADN, où ledit agent est caractérisé comme produisant un signal détectable quand il est lié à un
25 acide nucléique double brin, ledit signal pouvant être distingué du signal produit par ledit agent quand il n'est pas lié, et des réactifs pour amplification ;
- (b) à déterminer la quantité dudit signal produite par le mélange de l'étape (a) ;
- 30 (c) à traiter ledit mélange dans des conditions permettant l'amplification dudit acide nucléique cible ;
- (d) à déterminer la quantité dudit signal produite par ledit mélange de l'étape (c) ; et
- (e) à déterminer si une amplification a eu lieu.
- 35 2. Procédé selon la revendication 1, dans lequel ledit agent de liaison à l'ADN est en outre caractérisé comme produisant une quantité d'un signal détectable, quand ledit agent est lié à des acides nucléiques double brin, qui est plus grande que la quantité dudit signal détectable produite quand ledit agent est non-lié.
- 40 3. Procédé selon la revendication 1 ou 2, dans lequel ledit agent de liaison à l'ADN est un agent d'intercalation.
4. Procédé selon la revendication 3, dans lequel ledit agent d'intercalation est un colorant fluorescent.
5. Procédé selon la revendication 4, dans lequel, dans l'étape (e), une augmentation de la fluorescence indique qu'une amplification a eu lieu.
- 45 6. Procédé selon la revendication 5, dans lequel, dans les étapes (b) et (d), la quantité de signal produite est déterminée par exposition dudit mélange à une lumière UV, et, dans l'étape (e), par comparaison de la quantité relative du signal produite dans les étapes (b) et (d) pour déterminer si une amplification a eu lieu.
- 50 7. Procédé selon l'une quelconque des revendications 4 à 6, dans lequel ledit colorant fluorescent est le bromure d'éthidium.
8. Procédé selon l'une quelconque des revendications 4 à 7, dans lequel la quantité de signal produite est déterminée par utilisation d'un spectrofluorimètre.
- 55 9. Procédé selon l'une quelconque des revendications 5 à 8, dans lequel la quantité d'ADN cible dans ledit échantillon, avant amplification, est quantifiée par une détermination de la quantité de fluorescence avant et après amplification.

10. Procédé selon l'une quelconque des revendications 1 à 9, dans lequel ledit acide nucléique cible est le signe d'une maladie génétique ou infectieuse.
- 5 11. Procédé pour surveiller l'augmentation d'un ADN double brin pendant l'amplification d'un acide nucléique cible dans un échantillon, ledit procédé comprenant les étapes consistant :
 - (a) à mettre à disposition un mélange pour réaction d'amplification qui comprend ledit échantillon, un agent de liaison à l'ADN, où ledit agent est caractérisé comme produisant un signal détectable quand il est lié à un acide nucléique double brin, ledit signal pouvant être distingué du signal produit par ledit agent quand il n'est pas lié ;
 - 10 (b) à déterminer la quantité dudit signal produite par le mélange de l'étape (a);
 - (c) à traiter ledit mélange dans des conditions permettant l'amplification dudit acide nucléique cible ; et
 - (d) à déterminer pendant ladite étape d'amplification (c) la quantité dudit signal produite par ledit mélange pour réaction d'amplification.
- 15 12. Procédé selon la revendication 11, dans lequel, dans les étapes (b) et (d), on utilise une fibre optique et un spectrofluorimètre pour déterminer la quantité de signal produite pendant ladite étape de traitement.
- 20 13. Procédé selon la revendication 11 ou 12, dans lequel, dans l'étape (d), la quantité de signal est déterminée en continu tout au long de la réaction d'amplification.
- 25 14. Procédé selon l'une quelconque des revendications 11 à 13, dans lequel ledit agent de liaison à l'ADN est un agent d'intercalation.
15. Procédé selon la revendication 14, dans lequel ledit agent d'intercalation est un colorant fluorescent.
16. Procédé selon la revendication 15, dans lequel ledit colorant fluorescent est le bromure d'éthidium.
- 30 17. Procédé selon l'une quelconque des revendications 1 à 16, dans lequel ladite réaction d'amplification est une réaction d'amplification en chaîne par polymérase (PCR).
18. Procédé selon l'une quelconque des revendications 1 à 17, dans lequel la quantité d'acide nucléique cible dans l'échantillon est quantifiée.
- 35 19. Coffret pour amplifier un acide nucléique cible, ledit coffret comprenant un mélange pour amplification, destiné à une réaction d'amplification, ainsi qu'un agent d'intercalation, à la condition que ledit mélange ne contienne pas simultanément une polymérase ou des amorces.
- 40 20. Coffret selon la revendication 19, dans lequel ledit agent d'intercalation est un colorant fluorescent.
21. Coffret selon la revendication 20, dans lequel ledit colorant fluorescent est le bromure d'éthidium.
- 45 22. Coffret selon l'une quelconque des revendications 19 à 21, dans lequel ledit mélange pour amplification est un tampon PCR.
23. Coffret selon la revendication 22, dans lequel ledit bromure d'éthidium est présent à une concentration permettant de fournir un colorant de 0,15 à 40,6 μM dans une réaction d'amplification PCR.
- 50 24. Coffret selon la revendication 22 ou 23, dans lequel ledit mélange pour amplification comprend aussi du Tris HCl pH 8,0-8,3 et du KCl, chacun étant présent à une concentration convenant à l'amplification d'un acide nucléique cible dans une réaction d'amplification PCR.
- 55 25. Coffret selon l'une quelconque des revendications 19 à 23, qui comprend aussi une ADN-polymérase, du MgCl_2 et des dNTP.

Revendications pour les Etats contractants suivants : DE, FR, GB, IT

1. Procédé pour détecter un acide nucléique cible dans un échantillon, ledit procédé comprenant les étapes consistant :

5

(a) à mettre à disposition un mélange pour réaction d'amplification qui comprend ledit échantillon, un agent de liaison à l'ADN, où ledit agent est caractérisé comme produisant un signal détectable quand il est lié à un acide nucléique double brin, ledit signal pouvant être distingué du signal produit par ledit agent quand il n'est pas lié, et des réactifs pour amplification ;

10

(b) à déterminer la quantité dudit signal produite par le mélange de l'étape (a) à l'aide d'une fibre optique ;

(c) à traiter ledit mélange dans des conditions permettant l'amplification dudit acide nucléique cible ;

15

(d) à déterminer la quantité dudit signal produite par ledit mélange de l'étape (c) à l'aide d'une fibre optique ; et

(e) à déterminer si une amplification a eu lieu.

2. Procédé selon la revendication 1, dans lequel ledit agent de liaison à l'ADN est en outre caractérisé comme produisant une quantité d'un signal détectable, quand ledit agent est lié à des acides nucléiques double brin, qui est plus grande que la quantité dudit signal détectable produite quand ledit agent est non-lié.

20

3. Procédé selon la revendication 1 ou 2, dans lequel ledit agent de liaison à l'ADN est un agent d'intercalation.

25

4. Procédé selon la revendication 3, dans lequel ledit agent d'intercalation est un colorant fluorescent.

5. Procédé selon la revendication 4, dans lequel, dans l'étape (e), une augmentation de la fluorescence indique qu'une amplification a eu lieu.

30

6. Procédé selon la revendication 5, dans lequel, dans les étapes (b) et (d), la quantité de signal produite est déterminée par exposition dudit mélange à une lumière UV, et, dans l'étape (e), par comparaison de la quantité relative du signal produite dans les étapes (b) et (d) pour déterminer si une amplification a eu lieu.

35

7. Procédé selon l'une quelconque des revendications 4 à 6, dans lequel ledit colorant fluorescent est le bromure d'éthidium.

8. Procédé selon l'une quelconque des revendications 4 à 7, dans lequel la quantité de signal produite est déterminée par utilisation d'un spectrofluorimètre.

40

9. Procédé selon l'une quelconque des revendications 5 à 8, dans lequel la quantité d'ADN cible dans ledit échantillon, avant amplification, est quantifiée par une détermination de la quantité de fluorescence avant et après amplification.

10. Procédé selon l'une quelconque des revendications 1 à 9, dans lequel ledit acide nucléique cible est le signe d'une maladie génétique ou infectieuse.

45

11. Procédé pour surveiller l'augmentation d'un ADN double brin pendant l'amplification d'un acide nucléique cible dans un échantillon, ledit procédé comprenant les étapes consistant :

50

(a) à mettre à disposition un mélange pour réaction d'amplification qui comprend ledit échantillon, un agent de liaison à l'ADN, où ledit agent est caractérisé comme produisant un signal détectable quand il est lié à un acide nucléique double brin, ledit signal pouvant être distingué du signal produit par ledit agent quand il n'est pas lié ;

55

(b) à déterminer la quantité dudit signal produite par le mélange de l'étape (a) ;

(c) à traiter ledit mélange dans des conditions permettant l'amplification dudit acide nucléique cible ; et

(d) à déterminer pendant ladite étape d'amplification (c) la quantité dudit signal produite par ledit mélange

pour réaction d'amplification.

- 5 12. Procédé selon la revendication 11, dans lequel, dans les étapes (b) et (d), on utilise une fibre optique et un spectrofluorimètre pour déterminer la quantité de signal produite pendant ladite étape de traitement.
13. Procédé selon la revendication 11 ou 12, dans lequel, dans l'étape (d), la quantité de signal est déterminée en continu tout au long de la réaction d'amplification.
- 10 14. Procédé selon l'une quelconque des revendications 11 à 13, dans lequel ledit agent de liaison à l'ADN est un agent d'intercalation.
- 15 15. Procédé selon la revendication 14, dans lequel ledit agent d'intercalation est un colorant fluorescent.
16. Procédé selon la revendication 15, dans lequel ledit colorant fluorescent est le bromure d'éthidium.
17. Procédé selon l'une quelconque des revendications 1 à 16, dans lequel ladite réaction d'amplification est une réaction d'amplification en chaîne par polymérase (PCR).
- 20 18. Procédé selon l'une quelconque des revendications 1 à 17, dans lequel la quantité d'acide nucléique cible dans l'échantillon est quantifiée.
- 25 19. Coffret pour amplifier un acide nucléique cible, ledit coffret comprenant un mélange pour amplification, destiné à une réaction d'amplification, ainsi qu'un agent d'intercalation, à la condition que ledit mélange ne contienne pas simultanément une polymérase ou des amorces.
20. Coffret selon la revendication 19, dans lequel ledit agent d'intercalation est un colorant fluorescent.
21. Coffret selon la revendication 20, dans lequel ledit colorant fluorescent est le bromure d'éthidium.
- 30 22. Coffret selon l'une quelconque des revendications 19 à 21, dans lequel ledit mélange pour amplification est un tampon PCR.
23. Coffret selon la revendication 22, dans lequel ledit bromure d'éthidium est présent à une concentration permettant de fournir un colorant de 0,15 à 40,6 μM dans une réaction d'amplification PCR.
- 35 24. Coffret selon la revendication 22 ou 23, dans lequel ledit mélange pour amplification comprend aussi du Tris HCl pH 8,0-8,3 et du KCl, chacun étant présent à une concentration convenant à l'amplification d'un acide nucléique cible dans une réaction d'amplification PCR.
- 40 25. Coffret selon l'une quelconque des revendications 19 à 23, qui comprend aussi une ADN-polymérase, du MgCl_2 et des dNTP.




FIG. 2




FIG. 3



Homozygous
AA

Heterozygous
AS

Homozygous
SS

FIG. 4A







FIG. 4B







THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)